Emcure Pharmaceuticals Ltd. has announced a strategic price revision for its obesity drug Poviztra® (semaglutide injection), reducing prices by up to 55% in a bid to expand market penetration in India.
The revised monthly price for the 0.25 mg dose has been cut to Rs. 3,999, while higher doses have also seen significant reductions. The move translates to an average price drop of 47% across the product portfolio.
Poviztra®, a once-weekly injectable therapy, is a second brand of Novo Nordisk’s semaglutide, a globally established molecule with nearly a decade of clinical use.
Industry observers see the price cut as a key step in unlocking demand in a price-sensitive market like India, where obesity treatment adoption remains limited.
Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, “The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity.3 Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.”
